{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:51:58Z","timestamp":1790189518647,"version":"4.1.0"},"reference-count":52,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.45515","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T16:33:17Z","timestamp":1643646797000},"page":"e2145515","source":"Crossref","is-referenced-by-count":17,"title":["Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan"],"prefix":"10.1001","volume":"5","author":[{"given":"Yuki","family":"Takumoto","sequence":"first","affiliation":[{"name":"Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan"},{"name":"Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Sasahara","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Yamagata Prefectural Central Hospital, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Narimatsu","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan"},{"name":"Cancer Prevention and Cancer Control Division, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan"},{"name":"Graduate School of Health Innovation, Kanagawa University of Human Services, Kawasaki, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"issue":"5","key":"zoi211256r1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"zoi211256r6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2958\/suizo.22.e1","article-title":"Japan Pancreas Society, Pancreatic Cancer Registry Report of Japan 2007","volume":"22","author":"Committee for Pancreatic Cancer Registry","year":"2007","journal-title":"J Jpn Pancreas Soc"},{"issue":"6","key":"zoi211256r8","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi211256r9","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi211256r10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi211256r11","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi211256r12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/jhbp.2014.21.issue-10","article-title":"Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.","volume":"21","author":"Yanagimoto","year":"2014","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"12","key":"zoi211256r13","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/bjc.2012.183","article-title":"A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.","volume":"106","author":"Nakai","year":"2012","journal-title":"Br J Cancer"},{"issue":"2","key":"zoi211256r14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00280-013-2368-6","article-title":"Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.","volume":"73","author":"Sudo","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"zoi211256r15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi211256r18","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","article-title":"Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons.","volume":"11","author":"Jansen","year":"2008","journal-title":"Value Health"},{"issue":"3","key":"zoi211256r19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials.","volume":"17","author":"Salanti","year":"2008","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"zoi211256r20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"issue":"4","key":"zoi211256r21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"issue":"7521","key":"zoi211256r22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence.","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"issue":"15","key":"zoi211256r23","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1002\/(ISSN)1097-0258","article-title":"How vague is vague? a simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS.","volume":"24","author":"Lambert","year":"2005","journal-title":"Stat Med"},{"issue":"6","key":"zoi211256r25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"key":"zoi211256r29","doi-asserted-by":"publisher","first-page":"i08","DOI":"10.18637\/jss.v070.i08","article-title":"flexsurv: a platform for parametric survival modeling in R.","volume":"70","author":"Jackson","year":"2016","journal-title":"J Stat Softw"},{"issue":"15","key":"zoi211256r31","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi211256r32","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.","volume":"23","author":"Louvet","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi211256r33","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).","volume":"28","author":"Kindler","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi211256r34","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","article-title":"Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.","volume":"25","author":"Herrmann","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi211256r35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S1470-2045(05)70175-3","article-title":"Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.","volume":"6","author":"Reni","year":"2005","journal-title":"Lancet Oncol"},{"issue":"33","key":"zoi211256r36","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","article-title":"Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.","volume":"27","author":"Cunningham","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi211256r37","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.","volume":"28","author":"Philip","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"zoi211256r38","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","article-title":"Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi211256r39","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","article-title":"Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.","volume":"22","author":"Van Cutsem","year":"2004","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi211256r40","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1016\/j.ejca.2013.04.002","article-title":"Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.","volume":"49","author":"Rougier","year":"2013","journal-title":"Eur J Cancer"},{"issue":"10","key":"zoi211256r41","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.","volume":"28","author":"Colucci","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi211256r42","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005702","article-title":"A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.","volume":"96","author":"Lee","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"zoi211256r43","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/annonc\/mdv264","article-title":"A phase II\/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.","volume":"26","author":"O\u2019Neil","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"zoi211256r44","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdv133","article-title":"A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.","volume":"26","author":"Deplanque","year":"2015","journal-title":"Ann Oncol"},{"issue":"7","key":"zoi211256r45","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/cas.2015.106.issue-7","article-title":"Randomized phase II\/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.","volume":"106","author":"Yamaue","year":"2015","journal-title":"Cancer Sci"},{"issue":"5","key":"zoi211256r46","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00280-012-1822-1","article-title":"Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).","volume":"69","author":"Ozaka","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"zoi211256r47","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1200\/JCO.2001.19.15.3447","article-title":"Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.","volume":"19","author":"Bramhall","year":"2001","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi211256r48","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/annonc\/mdi309","article-title":"A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.","volume":"16","author":"Oettle","year":"2005","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi211256r49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","article-title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.","volume":"12","author":"Kindler","year":"2011","journal-title":"Lancet Oncol"},{"issue":"11","key":"zoi211256r50","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/annonc\/mds135","article-title":"BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.","volume":"23","author":"Gon\u00e7alves","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi211256r51","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology.","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"zoi211256r52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/1471-2407-14-471","article-title":"Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.","volume":"14","author":"Gresham","year":"2014","journal-title":"BMC Cancer"},{"key":"zoi211256r17","author":"Spiegelhalter","year":"2007"},{"key":"zoi211256r2","unstructured":"Noone? AM, Howlader? N, Krapcho? M, . SEER Cancer Statistics Review (CSR) 1975\u20132015. Updated September 10, 2018. Accessed February 26, 2019.https:\/\/seer.cancer.gov\/csr\/1975_2015\/"},{"key":"zoi211256r3","unstructured":"Cancer Registry and Statistics, Cancer Information Service, National Cancer Center, Japan. Cohort life table [in Japanese]. Accessed July 25, 2019. https:\/\/ganjoho.jp\/reg_stat\/statistics\/qa_words\/cohort01.html"},{"key":"zoi211256r4","unstructured":"Foundation for promotion of cancer research. Cancer statistics in Japan 2019. [in Japanese]. Accessed July 20, 2020. https:\/\/ganjoho.jp\/data\/reg_stat\/statistics\/brochure\/2019\/cancer_statistics_2019_fig_E.pdf?"},{"key":"zoi211256r5","unstructured":"Center for Cancer Control and Information Services, National Cancer Center. Monitoring of cancer incidence in Japan\u2014survival 2006\u20132008 report [in Japanese]. 2016. Accessed December 19, 2021. https:\/\/ganjoho.jp\/data\/en\/professional\/statistics\/files\/cancer_survival(1993-2008)E.xls?"},{"key":"zoi211256r7","unstructured":"Committee for Revision of Clinical Guidelines for Pancreatic Cancer, Japan Pancreas Society. Clinical practice guidelines for pancreatic cancer 2019 from the Japan Pancreas Society [in Japanese]. Accessed December 15, 2021. http:\/\/www.suizou.org\/pdf\/pancreatic_cancer_cpg-2019.pdf"},{"key":"zoi211256r16","unstructured":"Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developer\u2019s handbook. November 2015. Accessed December 14, 2021. https:\/\/www.sign.ac.uk\/our-guidelines\/sign-50-a-guideline-developers-handbook\/"},{"key":"zoi211256r24","unstructured":"Dias? S, Welton? NJ, Sutton? AJ, . A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. NICE Decision Support Unit evidence synthesis technical support document 2. 2011. Accessed 25 July 2019. https:\/\/scharr.dept.shef.ac.uk\/nicedsu\/technical-support-documents\/evidence-synthesis-tsd-series"},{"key":"zoi211256r26","unstructured":"Woods? B, Sideris? E, Palmer? S, . NICE DSU technical support document 19. partitioned survival analysis for decision modelling in health care: a critical review. 2017. Accessed July 25, 2019. http:\/\/www.nicedsu.org.uk"},{"key":"zoi211256r27","unstructured":"Rohatgi? A. WebPlotDigitizer user manual; version 4.3. Accessed August 29 2020. https:\/\/automeris.io\/WebPlotDigitizer\/userManual.pdf"},{"key":"zoi211256r28","unstructured":"R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. Accessed December 14, 2021. http:\/\/www.R-project.org"},{"key":"zoi211256r30","unstructured":"Baio? G. Survival analysis in health economic evaluation. Accessed December 14, 2021. https:\/\/github.com\/giabaio\/survHE"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2788498\/takumoto_2022_oi_211256_1643043091.84052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T16:33:25Z","timestamp":1643646805000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2788498"}},"subtitle":["A Systematic Review and Network Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.45515","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]}}}